370 related articles for article (PubMed ID: 25804477)
1. The inflammasome and IL-1β: implications for the treatment of inflammatory diseases.
Satoh T; Otsuka A; Contassot E; French LE
Immunotherapy; 2015; 7(3):243-54. PubMed ID: 25804477
[TBL] [Abstract][Full Text] [Related]
2. Gain of function mutation and inflammasome driven diseases in human and mouse models.
Cordero MD; Alcocer-Gómez E; Ryffel B
J Autoimmun; 2018 Jul; 91():13-22. PubMed ID: 29610014
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
Landmann EC; Walker UA
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
[TBL] [Abstract][Full Text] [Related]
4. Contribution of the inflammasomes to autoinflammatory diseases and recent mouse models as research tools.
Heymann MC; Rösen-Wolff A
Clin Immunol; 2013 Jun; 147(3):175-84. PubMed ID: 23411032
[TBL] [Abstract][Full Text] [Related]
5. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases.
Bettiol A; Lopalco G; Emmi G; Cantarini L; Urban ML; Vitale A; Denora N; Lopalco A; Cutrignelli A; Lopedota A; Venerito V; Fornaro M; Vannacci A; Rigante D; Cimaz R; Iannone F
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999610
[TBL] [Abstract][Full Text] [Related]
6. Canakinumab for the treatment of chronic obstructive pulmonary disease.
Rogliani P; Calzetta L; Ora J; Matera MG
Pulm Pharmacol Ther; 2015 Apr; 31():15-27. PubMed ID: 25660162
[TBL] [Abstract][Full Text] [Related]
7. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD; McDermott MF
Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
[TBL] [Abstract][Full Text] [Related]
8. [CAPS treatment].
Jiménez Treviño S; Ramos Polo E
Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
[TBL] [Abstract][Full Text] [Related]
9. [Canakinumab: a promising treatment in rheumatology].
Fabreguet I; So A
Rev Med Suisse; 2012 Jan; 8(323):57-60. PubMed ID: 22303742
[TBL] [Abstract][Full Text] [Related]
10. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β.
Bracey NA; Beck PL; Muruve DA; Hirota SA; Guo J; Jabagi H; Wright JR; Macdonald JA; Lees-Miller JP; Roach D; Semeniuk LM; Duff HJ
Exp Physiol; 2013 Feb; 98(2):462-72. PubMed ID: 22848083
[TBL] [Abstract][Full Text] [Related]
11. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
Walsh GM
Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
[TBL] [Abstract][Full Text] [Related]
12. Canakinumab for treatment of cryopyrin-associated periodic syndrome.
Feist E; Burmester GR
Expert Opin Biol Ther; 2010 Nov; 10(11):1631-6. PubMed ID: 20955115
[TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen species activated NLRP3 inflammasomes prime environment-induced murine dry eye.
Zheng Q; Ren Y; Reinach PS; She Y; Xiao B; Hua S; Qu J; Chen W
Exp Eye Res; 2014 Aug; 125():1-8. PubMed ID: 24836981
[TBL] [Abstract][Full Text] [Related]
14. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome.
Mitroulis I; Skendros P; Ritis K
Eur J Intern Med; 2010 Jun; 21(3):157-63. PubMed ID: 20493414
[TBL] [Abstract][Full Text] [Related]
15. Cryopyrin-associated periodic syndromes: background and therapeutics.
Kubota T; Koike R
Mod Rheumatol; 2010 Jun; 20(3):213-21. PubMed ID: 20140476
[TBL] [Abstract][Full Text] [Related]
16. IL-1 blockade in autoinflammatory syndromes.
Jesus AA; Goldbach-Mansky R
Annu Rev Med; 2014; 65():223-44. PubMed ID: 24422572
[TBL] [Abstract][Full Text] [Related]
17. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
[TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species activated NLRP3 inflammasomes initiate inflammation in hyperosmolarity stressed human corneal epithelial cells and environment-induced dry eye patients.
Zheng Q; Ren Y; Reinach PS; Xiao B; Lu H; Zhu Y; Qu J; Chen W
Exp Eye Res; 2015 May; 134():133-40. PubMed ID: 25701684
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and Clinical Examination of Autoinflammatory Syndrome].
Ida H
Rinsho Byori; 2015 May; 63(5):598-604. PubMed ID: 26524899
[TBL] [Abstract][Full Text] [Related]
20. The nucleotide-binding domain and leucine-rich repeat protein-3 inflammasome is not activated in airway smooth muscle upon toll-like receptor-2 ligation.
Hirota JA; Im H; Rahman MM; Rumzhum NN; Manetsch M; Pascoe CD; Bunge K; Alkhouri H; Oliver BG; Ammit AJ
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):517-24. PubMed ID: 23614732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
